Analysis and data insight
Analysis and data insight RSS Feed RSS

Health professional touching screen, digital/medical icons
AI partnerships ‘move the industry forward’

Trial recruitment, retention improved but drop-outs persist in late studies

Feb. 11, 2020
By Marie Powers
Multiple tactics employed by the biopharma industry to improve the recruitment and retention of participants in clinical trials seem to be paying off. More than three of four (77%) studies now fully enroll on or ahead of schedule, according to researchers at the Tufts Center for the Study of Drug Development (CSDD), reporting in the January/February Tufts CSDD Impact Report on global recruitment performance benchmarks.
Read More
Test tube, dropper

Phase I clinical trials: January 2020

Feb. 7, 2020
Therapeutic area data reported by biopharma companies on phase I trials in January 2020, including: Adaptimmune, Agenus, Astellas, Autolus, Aveo Oncology, Bellicum, Biotheryx, Briacell, Cellectis, Celyad, Cstone, Cytodyn, Exelixis, Faron, Forma, Geneos, Glycomimetics, Ikena, Immunitybio, Inhibrx, Invectys, Isofol Medical, Leap, Lipomedix, Medigene, Midatech, Miragen, Nantkwest, NEC, Oric, Oxford, Pharmajet, Pharmamar, Rafael, SQZ, Sun, Syros, Targovax, Tmunity, Transgene, Trovagene, Unum.
Read More

Phase II clinical trials: January 2020

Feb. 7, 2020
Therapeutic area data reported by biopharma companies on phase II trials in January 2020, including: Acceleron, Akcea, Bergenbio, Cytokinetics, Daiichi Sankyo, Delmar, Durect, Galapagos, Hutchison China, I-Mab, Immutep, Iovance, Kalvista, Khondrion, Orphazyme, Pellepharm, Tenax, Tolero, Tyme, VBL, Xeris, Zai Lab.
Read More

Phase III clinical trials: January 2020

Feb. 7, 2020
Therapeutic area data reported by biopharma companies on phase III trials in January 2020, including: Abbvie, Astrazeneca, Beigene, Biofrontera, Eli Lilly, EMD Serono, Erytech, Evolus, Incyte, Innovent, Isofol Medical, Kala, Kyowa Kirin, Lipidor, Merck, Nucana, Orion, Rafael, Roche, Sellas Life Sciences, VBL, Verastem.
Read More

Investors looking for repeat performance from drug developers

Feb. 4, 2020
By Peter Winter
Investors in small and midsized biopharma companies were certainly rewarded in 2019, with group members in the BioWorld Drug Developers index on a tear. The price-weighted index returned 40% in value thanks to a steady flow of positive regulatory and clinical trial results from the companies throughout the year. However, investors may be less impressed with the start they have made this year, with the index dipping 8.4% in January.
Read More